Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The breast cancer resistance protein (BCRP/ABCG2) plays a major role in the multidrug resistance of cancers toward chemotherapeutic treatments. It was demonstrated that cholesterol regulates the ABCG2 activity, suggesting that lower levels of membrane cholesterol decrease the ABCG2 activity in mammalian cells. However, the precise mechanism remains unclear. To better understand the role of cholesterol in the ABCG2 activity, we studied the ABCG2-mediated efflux of different substrates in the presence of different concentrations of cholesterol. Moreover, we synthetized derivatives of cholesterol linked either to known ABCG2 inhibitors or fluorescents probes. A chalcone-cholesterol was synthetized to investigate the influence of cholesterol on ABCG2 inhibition, and a BODIPY-cholesterol was developed to track cholesterol trafficking on mammalian cells and investigate the behavior of cholesterol as an ABCG2 substrate. The obtained results with three different substrates of ABCG2 showed that cholesterol did not affect the intracellular amount of substrates nor the transport activity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005470 | PMC |
| http://dx.doi.org/10.1002/cmdc.202400712 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rutin Alleviates Breast Cancer Resistance to Tamoxifen By Downregulating ABC Transporters, Inducing ROS Generation and Resetting Redox Status.
J Biochem Mol Toxicol
September 2025
Biochemistry Division, Chemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.
Breast cancer is one of the most lethal cancers in women worldwide. Tamoxifen (TAM), a nonsteroidal antiestrogen, is a highly successful treatment for breast cancer. However, developed resistance to TAM can substantially impair chemotherapy efficacy, resulting in poor prognosis and cancer recurrence.
View Article and Find Full Text PDFProgress in animal models for studying hyperuricemia.
Front Pharmacol
August 2025
The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, China.
Hyperuricemia (HUA) is a prevalent metabolic disorder driven by dysregulated purine metabolism and impaired urate excretion, and robust animal models are critical for elucidating its pathophysiology and guiding therapy development. This review systematically examines chemically induced, gene-edited, environmental, exercise and microbiota-based HUA models across rodents, poultry, primates, zebrafish and silkworms, highlighting each model's strengths and limitations in mimicking human uric acid handling. We discuss how these models have validated standard urate-lowering treatments-such as xanthine oxidase inhibitors and uricosurics-and uncovered emerging therapeutic targets, including the gut-NLRP3 inflammasome axis and SIRT1-mediated ABCG2 regulation.
View Article and Find Full Text PDFFucoidan-driven Bacteroides xylanisolvens HS-1 alleviates hyperuricemia by promoting intestinal uric acid excretion via the PPARγ/ABCG2 signaling pathway.
Int J Biol Macromol
September 2025
Department of Gastroenterology, The Affiliated Hospital of Qingdao University, Qingdao, 266001, PR China. Electronic address:
The rising prevalence of hyperuricemia and associated complications present a substantial global health challenge. Fucoidan, a natural sulfate-rich polysaccharide degraded by gut microbiota, is under investigation as a potential therapeutic agent for reducing uric acid levels. However, the precise mechanism underlying its effects remains unclear.
View Article and Find Full Text PDFLoss of CD90 alters EMT-associated features and drug sensitivity in U-CH1 chordoma cells.
Naunyn Schmiedebergs Arch Pharmacol
September 2025
Department of Medical Genetics, School of Medicine, Yeditepe University, Istanbul, 34755, Turkey.
Chordoma is a rare, slow-growing malignancy of notochordal origin characterized by a high degree of chemoresistance and limited therapeutic responsiveness. Despite advances in molecular profiling, the mechanisms underlying its cellular plasticity and therapy evasion remain incompletely defined. Emerging evidence across solid tumors suggests that cancer stem-like cells (CSCs) and the epithelial-to-mesenchymal transition (EMT) play central roles in driving tumor progression, metastatic potential, and drug resistance.
View Article and Find Full Text PDFNew players from the old chalcone scaffold: Synthesis, identification, and characterization of new potent ABCG2 inhibitors.
Eur J Med Chem
December 2025
Graduate Program in Pharmaceutical Sciences, Laboratory of Cancer Drug Resistance, Federal University of Parana, Curitiba, 80210-170, PR, Brazil; Graduate Program in Cell and Molecular Biology, Federal University of Parana, Curitiba, PR, Brazil. Electronic address:
The ABCG2 transporter is an efflux pump that can transport various anticancer drugs and is strongly associated with multidrug resistance (MDR) in cancer. A promising strategy to combat MDR mediated by this transporter is through functional inhibition. However, there are currently no potent selective ABCG2 inhibitors in clinical trials.
View Article and Find Full Text PDF